Edoxaban Versus Dalteparin in Cancer-Associated VTE – JTH
Journal of Thrombosis and Haemostasis (JTH) shared on LinkedIn about a recent article by Nick van Es et al, adding:
”The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai VTE Cancer trial
Novel win ratio analysis comparing edoxaban versus dalteparin in cancer-associated VTE reveals no significant difference between treatments when evaluating hierarchically prioritized outcomes including mortality, recurrent events, and bleeding complications.”
Title: The win ratio for evaluating edoxaban vs dalteparin for cancer-associated venous thromboembolism: an analysis of the randomized Hokusai Venous Thromboembolism Cancer trial
Authors: Nick van Es, Luuk Scheres., Kristen Sanfilippo, Harry Buller, Marc Carrier, Marcello Di Nisio, Michael A. Grosso, Renato D. Lopes, William McIntyre, Björn Redfors, Annelise Segers, Peter Verhamme, Jeff Weitz, Patrick Bossuyt, Deborah Siegal
Read the Full Article on JTH
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 21, 2026, 10:10Pete Stibbs: The Evolving Landscape of VTE Management
-
Aug 21, 2026, 09:58Nishant K Mishra։ When Epilepsy Meets Anticoagulation
-
Aug 21, 2026, 09:07Sujal Lohana: Building a Better Blood Donor–Seeker App
-
Aug 21, 2026, 08:55Robert Sidonio: Connecting Experts in Bleeding and Clotting Disorders
-
Aug 21, 2026, 08:44Gladys Delancey: Understanding Blood Clots and Their Warning Signs
-
Aug 21, 2026, 08:32Brian Freeman: Supporting Innovation in Rare Blood Disorders
-
Aug 21, 2026, 07:46Mallikarjuna Rao Dubisetty: Thalassemia Awareness – What Every Parent Should Know
-
Aug 20, 2026, 19:46Haseeb Raza: A Practical Guide to Managing Bleeding on Anticoagulant Therapy
-
Aug 20, 2026, 19:44Harshi Peiris: 2026 Cholesterol Guidelines Bring Earlier and More Precise Risk Assessment